ASCO 2021 | Transfusion independence and momelotinib in myelofibrosis
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discussess the association between transfusion independence and overall survival (OS) in patients with myelofibrosis receiving momelotinib. Momelotinib is a JAK1, JAK2 and ACVR1 inhibitor which has previously demonstrated clinical activity against features of myelofibrosis including anemia, constitutional symptoms and splenomegaly in the SIMPLIFY-1 (NCT01969838) and SIMPLIFY-2 (NCT02101268) trials. Subgroup analysis of patients in the SIMPLIFY-1 and SIMPLIFY-2 trials compared patients who achieve transfusion independence(TI) by week 24 to those who did not achieve TI by week 24. Week 24 TI rates were higher in the momelotinib arms for both trials. Prof. Mesa also comments on novel data from the JAKARTA2 trial (NCT01523171). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Ruben Mesa, MD, has participated in a consultancy role with Novartis, Sierra Onc, LaJolla, Pharma and Constellation; and has received research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI and Constellation.
